Motif Bio PLC Notification of change in holding of shareholder (0565D)

TIDMMTFB

RNS Number : 0565D

Motif Bio PLC

24 April 2017

24 April 2017

Motif Bio plc

("Motif Bio" or the "Company")

Notification of change in holding of significant shareholder

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 21 April 2017 by Sabby Healthcare Master Fund Ltd ("Sabby") that as at 10 April 2017, Sabby's interest in shares in the Company to which voting rights are attached, being ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), had fallen from an interest in 17,191,980 Ordinary Shares (held by way of American Depositary Shares ("ADSs")), representing 9.52% of the Company's issue share capital, to an interest in 5,887,050 Ordinary Shares (held by way of 157,698 ADSs and 2,733,090 Ordinary Shares), representing 3% of the Company's issued share capital.

For further information please contact:

 
 Motif Bio plc                                                  [e-mail] 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                              [phone] 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/David 
  Hignell 
  John Howes/Rob Rees (Broking)                               [phone] 
 Walbrook PR Ltd. (FINANCIAL       [phone] or [e-mail] 
  PR & IR)                                               Mob: [phone] 
  Paul McManus                                           Mob: [phone] 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                               [phone] 
 

Notes to Editors:

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUOABRBUASUAR

(END) Dow Jones Newswires

April 24, 2017 02:01 ET (06:01 GMT)